NASDAQ:MGEN - Miragen Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.61 -0.14 (-2.95 %)
(As of 10/22/2018 04:00 PM ET)
Previous Close$4.75
Today's Range$4.59 - $4.84
52-Week Range$4.38 - $10.70
Volume89,455 shs
Average Volume196,935 shs
Market Capitalization$145.34 million
P/E Ratio-3.34
Dividend YieldN/A
Beta1.33
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan. The company also develops MRG-107, an inhibitor of miR-155 for treating neuronal amyotrophic lateral sclerosis, and other neurodegenerative indications, including spinal cord injury. It also develops preclinical product candidates for treating various indications, including oncology, visual pathologies, neurodegeneration, and hearing loss. Miragen Therapeutics, Inc. has a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. The company was founded in 2006 and is based in Boulder, Colorado.

Receive MGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGEN
CUSIPN/A
Phone720-643-5200

Debt

Debt-to-Equity Ratio0.15
Current Ratio18.98
Quick Ratio18.98

Price-To-Earnings

Trailing P/E Ratio-3.34
Forward P/E Ratio-4.12
P/E GrowthN/A

Sales & Book Value

Annual Sales$4 million
Price / Sales35.27
Cash FlowN/A
Price / CashN/A
Book Value$1.73 per share
Price / Book2.66

Profitability

EPS (Most Recent Fiscal Year)($1.38)
Net Income$-26,510,000.00
Net Margins-261.47%
Return on Equity-46.99%
Return on Assets-38.14%

Miscellaneous

Employees65
Outstanding Shares30,600,000
Market Cap$145.34 million

Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions

What is Miragen Therapeutics' stock symbol?

Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics Inc (NASDAQ:MGEN) announced its quarterly earnings data on Tuesday, August, 7th. The medical research company reported ($0.29) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.29). The medical research company earned $2.18 million during the quarter, compared to analysts' expectations of $0.83 million. Miragen Therapeutics had a negative return on equity of 46.99% and a negative net margin of 261.47%. View Miragen Therapeutics' Earnings History.

When is Miragen Therapeutics' next earnings date?

Miragen Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 14th 2018. View Earnings Estimates for Miragen Therapeutics.

What price target have analysts set for MGEN?

9 Wall Street analysts have issued 12 month price targets for Miragen Therapeutics' shares. Their predictions range from $13.00 to $19.00. On average, they expect Miragen Therapeutics' share price to reach $16.3571 in the next year. This suggests a possible upside of 254.8% from the stock's current price. View Analyst Price Targets for Miragen Therapeutics.

What is the consensus analysts' recommendation for Miragen Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Miragen Therapeutics.

What are Wall Street analysts saying about Miragen Therapeutics stock?

Here are some recent quotes from research analysts about Miragen Therapeutics stock:
  • 1. Cann analysts commented, "We estimate remlarsen (MRG-201) could be a modest revenue contributor to miRagen starting in 2024 in the prevention of keloid formation. The preclinical data presented today, and previously presented, are encouraging for this compound clinically for the prevention of corneal and retinal fibrosis and could result in an additional setting for remlarsen (MRG-201). The timing of the phase II study, which initiated in with these preclinical data presented today, support our outlook for miRagen in the anti-fibrotic setting, and could result in upside to our outlook from corneal fibrosis treatment." (10/1/2018)
  • 2. According to Zacks Investment Research, "Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. " (8/11/2018)
  • 3. Wedbush analysts commented, "Athersys announced an expanded agreement with Helios KK (6927JP – NR) that includes additional indications and will bring in an additional $20M in capital to Athersys. In association with this deal, Dr. Hardy Kagimoto, CEO of Helios has been nominated for election (June 18, 2018) to the Athersys board of directors." (6/7/2018)

Who are some of Miragen Therapeutics' key competitors?

Who are Miragen Therapeutics' key executives?

Miragen Therapeutics' management team includes the folowing people:
  • Dr. William Stuart Marshall Ph.D., Co-Founder, Pres, CEO & Director (Age 54)
  • Mr. Adam Scott Levy, Chief Bus. Officer (Age 40)
  • Dr. Paul D. Rubin, Exec. VP of R&D (Age 64)
  • Eric N. Olson, Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 73)

How do I buy shares of Miragen Therapeutics?

Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Miragen Therapeutics' stock price today?

One share of MGEN stock can currently be purchased for approximately $4.61.

How big of a company is Miragen Therapeutics?

Miragen Therapeutics has a market capitalization of $145.34 million and generates $4 million in revenue each year. The medical research company earns $-26,510,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Miragen Therapeutics employs 65 workers across the globe.

What is Miragen Therapeutics' official website?

The official website for Miragen Therapeutics is http://www.signalgenetics.com.

How can I contact Miragen Therapeutics?

Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]


MarketBeat Community Rating for Miragen Therapeutics (NASDAQ MGEN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe MGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel